350 rub
Journal Technologies of Living Systems №3 for 2012 г.
Article in number:
Activators and inhibitors of angiogenesis in tumors
Keywords: angiogenesis VEGF HIF antitumor therapy
Authors:
A.Yu. Nasarenko, О.М. Кuznetsova, E.Yu. Russo, U.R. Mаmеdov, Т.Т. Beresov
Abstract:
Angiogenesis, a process of formation of new blood vessels, is necessary for tumor development. New vessels provide tumor with oxygen and nutrients required for growth. Moreover, emergence of angiogenesis activators is associated with malignancy and indicates unfavorable disease prognosis. In 2004 FDA approved the first antiangiogenic compound bevacizumab for colorectal cancer treatment. It cleared the way for other compounds aimed at suppression of vascular growth in tumors. The review is dedicated to some basic mechanisms of angiogenesis involving signaling pathways and their inhibitors. The article presents the newest data about antiangiogenic antitumor therapy. The structure and mechanisms of action are presented for the medications described in the survey. Bevacizumab, aflibercept, sunitinib, sorafenib, ekhinomicin, hetomin, 17-AAG, PX-12, mTOR rapamicin inhibitors, cyclophosphamide, paclitaxel, doxorubicin, vincristine have a wide range of administrations in modern therapy, clinical trials are conducted as the mechanisms of their antiangiogenic action is not clear enough. Further investigations of receptors, ligands and morphological characters are necessary as standard biomarker for antiangiogenic therapy prescibtion is currently undefined.
Pages: 49-57
References
  1. Folkman J. Tumor angiogenesis: therapeutic implications // New England Journal of Medicine. 1971. V. 285. P. 1182 - 1186.
  2. Grothey A., Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules // Nature Reviews Clinical Oncology. 2009. V. 6. P. 507 - 518.
  3. Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors // Nature Medicine. 2003. V. 9. P. 669 - 676.
  4. Ferrara N. Vascular endothelial growth factor // Arteriosclerosis Thrombosis and Vascular Biology. 2009. V. 29. P. 789 - 791.
  5. Cohen M.H., Gootenberg J., Keegan P. et al. FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer // The Oncologist. V. 12.№ 3. P. 356 - 361.
  6. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer // New Engl. J. Med. 2004. V. 350. P. 2335 - 2342.
  7. Van Meter M.E.M., Kim E.S. Bevacizumab: current updates in treatment // Current Opinion in Oncology. 2010. V. 22. № 6. P. 586 - 591.
  8. Hansel T.T., Kropshofer H., Singer T. et al. The safety and side effects of monoclonal antibodies // Nature Reviews Drug Discovery. 2010. V. 9. P. 325 - 338.
  9. Mailliez A., Baldini C., Van J.T., et al. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients // Brit. J. Cancer. 2010. V. 103. P. 772 - 775.
  10. Badgwell B.D., Camp E.R., Feig B., et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature // Ann. Oncol. 2008. V. 19. № 3. P. 577 - 582.
  11. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforations in patients with cancer treated by bevacizumab: a meta-analysis // The Lancet Oncology. 2009. V. 10. № 6. P. 559 - 568.
  12. Konnor J., Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity // Clinical Colorectal Cancer. 2004. V. 4. Suppl. 2. P. 81 - 85.
  13. Dupont J., Schwartz L., Koutcher J. et al. Phase I and pharmokinetic of VEGF Trap administered subcutaneously (sc) to patients (pt) with advanced solid malignancies // J. Clin. Oncol. 2004. V.22. № 15. P. 3009.
  14. Tew W.P., Colombo M., Ray-Coquard I. et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study.
  15. Staton C.A., Brown N.J., Reed M.W. Current status and future prospects for antiangiogenic therapies in cancer // Expert Opinion Drug Discovery. 2009. V. 4. P. 961 - 979.
  16. Gan H.K., Seruga B., Knox J.J. Sunitinib in solid tumors // Expert Opinion on Investigational Drugs. 2009. V. 18. P. 821 - 834.
  17. Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma // J. Clin. Oncol. 2009. V. 27. № 22. P. 3584 - 3590.
  18. Demetri G.D., Huang X., Garret C.R. et al. Novel statistical analysis of long-term survival to account for crossover in phase III of sunitinib (SU) versus placebo (PL) in advanced GIST after imatinib (IM) failure (abstract) // J. Clin. Oncol.- ACSO Annual Meeting Proceedings. 2008. V. 26. P. 15S. 10524.
  19. Kulke M.H., Lenz H.-J., Meropol N.J. et al. Activity of sunitinib in patients with advanced neuroendocrine tumors // J. Clin. Oncol. 2008. V. 26. № 20. P. 3403 - 3410.
  20. Sonpavde J., Periman P.O., Bernold D. et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy // Ann. Oncol. 2009. V. 21. № 2. P. 319 - 324.
  21. Biagi J.J., Oza A.M., ChalChal H.I. et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials group study // Ann. Oncol. 2010. doi: 10.1093/annonc/mdq357.
  22. Wilhelm S.M., Adnane L., Newell P. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling // Molecular Cancer Therapeutics. 2008. V. 7. P. 3129 - 3140.
  23. Wilhelm S.M., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis // Cancer Res. 2004. V. 64. P. 7099 - 7109.
  24. Guevremont C., Jeldres C., Perrotte P. et al. Sorafenib in the management of metastatic renal cell carcinoma // Current Oncol. 2009. V. 16. Suppl. 1. P. 27 - 32.
  25. Kane R.C., Farrell A.T., Madabushi R. et al. Surafenib for the treatment of unresectable hepatocellular carcinoma // The Oncologist. 2009. V. 14. № 1. P. 95 - 100.
  26. Blumenschein G.R. Jr., Gatzemeier U., Fossella F. et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed of refractory, advanced non-small-cell lung cancer // J. Clin. Oncol. 2009. V. 27. № 26.  P. 4274 - 4280.
  27. Aragon-Ching J.B., Jain L., Gulley J.L. et al. Final analysis of phase II trial using sorafenib for metastatic castration-resistant prostate cancer // BJU International. 2009. V. 103. № 12. P. 1636 - 1640.
  28. Lichtenberger B.M., Tan P.K., Niederleithner H. et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development // Cell. 2010. V. 140. № 2. P. 268 - 279.
  29. Frieze D.A. Current status of cetuximab for the treatment of patients with solid tumors // The Annals of Pharmacotherapy. 2006. V. 40. № 2. P. 241 - 250.
  30. Bonner J.A., Harari P.M., Giralt J. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival // The Lancet Oncology. 2010. V. 11. № 1. P. 21 - 28.
  31. Pirker R., Pereira J.R., Szczesna A. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial // The Lancet. 2009. V. 373. № 9674. P. 1525 - 1531.
  32. Gravalos C., Cassinello J., Garcia-Alfonso P. et al. Integration of panitumumab into the treatment of colorectal cancer // Critical Reviews in Oncology/Hematology. 2010. V. 74. № 1. P. 16 - 26.
  33. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer // J. Clin. Oncol. 2010. V. 28. № 7. P. 1254 - 1261.
  34. Weidemann A., Johnson R.S. Biology of HIF-α // Cell Death and Differentiation. 2008. V. 15. P.621 ? 627.
  35. Schofield C.J., Ratcliffe P.J. Signalling hypoxia by HIF hydroxylases // Biochemical and Biophysical Research Communications. 2005. V. 38. P.617 ? 626.
  36. Talks K.L., Turley H., Gatter K.C. et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages // Am. J. Pathol. 2000. V. 157. P. 411 - 421.
  37. Giatromanolaki A., Sivridis E., Fiska A. et al. Hypoxia inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas // Applied Immunohistochemistry and Molecular Morphology. 2006. V. 14. P. 78 - 82.
  38. Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions // FEBS J. 2007. V. 274. № 21. P.5533 - 5542.
  39. Gradishar W.G., Vogelzang N.J., Kilton L.J. et al. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study // Investigational New Drugs. 1995. V. 13. P. 171 - 174.
  40. Nickols N.G., Jacobs C.S., Farkas M.E. et al. Modulating hypoxia-inducible transcription by the HIF-1‑DNA interface // ACS Chemical Biology. 2007. V. 2. № 8. P. 561 - 571.
  41. Kung A.L., Wang S., Klco J.M. et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription // Nature Medicine. 2000. V. 6. P. 1335 - 1340.
  42. Kung A.L., Zabludoff S.D., France D.S. et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway // Cancer Cell. 2004. V. 6. P. 33 - 43.
  43. Cook K.M., Hilton S.T., Mecinovic J. et al.Epidi-
    thiodiketopiperazines block the interaction between hypoxia-inducible factor-1α (HIF-1α) and p300 by a zinc ejection mechanism // J. Biol. Chemistry. 2009. V. 284. P. 26831 - 26838.
  44. Bohonowych J.E., Gopal U., Isaacs J.S. HSP90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls // J. Oncol. 2010. doi: 10.1155/2010/412985
  45. Pick L., Kluger Y., Giltnane J.M. et al. High HSP90 expression is associated with decreased survival in breast cancer // Cancer Res. 2007. V. 67. P. 2932 - 2937.
  46. Solit D.B., Chiosis G. Development and application of HSP90 inhibitors // Drug Discovery Today. 2008. V. 13. P. 38 - 43.
  47. Taldone T., Gozman A., Maharaj R. et al. Targeting HSP90: small-molecule inhibitors and their clinical development // Current Opinion in Pharmacology. 2008. V. 8. P. 370 - 374.
  48. Karlenius T.C., Tonissen K.F. Thioredoxin and cancer: a role for thioredoxin in all states of tumor oxygenation // Cancers. 2010. V. 2. P. 209 - 232.
  49. Ramanathan R.K., Dragovich T., Richards D. et al. Results from phase Ib studies of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies // J. Clin. Oncol. ACSO Annual Meeting Proceedings. 2009. V. 27. № 15. P. 2571.
  50. Hixon M.L., Paccagnella L., Millham R. et al. Development of IGF-IR/PI3I/AKT/mTOR pathway // Reviews on Recent Clinical Trials. 2010. V. 5. № 3. P. 189 - 208.
  51. Fox S.B., Generali D.G., Harris A.L. Breast tumor angiogenesis // Breast Cancer Research. 2007. V.9.